Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. News
  7. Summary
    4523   JP3160400002

EISAI CO., LTD.

(4523)
  Report
Delayed Japan Exchange  -  01:00:00 2023-02-07 am EST
7597.00 JPY   -0.45%
05:31aEisai Records 35% Decline in Fiscal Nine-month Profit on Higher Operating Expenses
MT
02/06Lower Yen Raises Tokyo Stock Market
MT
02/06Jefferies Adjusts Eisai's Price Target to 8,000 Yen From 10,000 Yen, Keeps at Hold
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

(OFFICIAL)-UPDATE 2-Japanese drugmaker Eisai's shares drop on report of death in Alzheimer's trial

11/29/2022 | 02:06am EST

TOKYO, Nov 29 (Reuters) - Shares in Japanese drugmaker Eisai Co fell more than 6% on Tuesday after a report that a woman who was enrolled in a trial of the company's Alzheimer's disease treatment had died from brain haemorrhage.

The haemorrhage occurred after the woman, who was receiving the experimental drug developed by Eisai and U.S. partner Biogen Inc, suffered a stroke and was given a medicine known as tissue plasminogen activator (tPA) to clear blood clots, journal Science.org reported on Sunday.

Some analysts said it was not clear if use of the drug, lecanemab, was raising the risk of bleeding, and cautioned against the use of blood thinners with the drug.

"We think the interpretation that lecanemab is the causative factor is aggressive. This patient clearly went into crisis following tPA administration," Baird analyst Brian Skorney said in a note.

This is the second media report of a death among patients who were enrolled in the lecanemab trial. A man in his 80s who was receiving a blood thinner died in June, according to a report by health journal STAT in late October.

Eisai said in a statement on Monday that all available safety information indicates lecanemab therapy is not associated with an increased risk of death overall. It said it could not provide any information about specific patients "to protect the privacy of patients".

Shares of Eisai dropped 6.2% to 8,988 yen on Tuesday, leading decliners on the benchmark Nikkei index, which closed 0.5% lower. Shares in Biogen fell 4.3% on Monday.

Biogen and Eisai are expected to present detailed data from their late-stage study results later in the day.

Lecanemab was shown to slow cognitive and functional decline in a large trial of patients in the early stages of Alzheimer's disease, the companies said in September. (Reporting by Rocky Swift in Tokyo and Raghav Mahobe and Khushi Mandowara in Bengaluru; Editing by Cynthia Osterman and Devika Syamnath)


ę Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. 1.64% 288.28 Delayed Quote.2.42%
EISAI CO., LTD. -0.45% 7597 Delayed Quote.-12.33%
NIKKEI 225 -0.03% 27685.47 Real-time Quote.6.13%
All news about EISAI CO., LTD.
05:31aEisai Records 35% Decline in Fiscal Nine-month Profit on Higher Operating Expenses
MT
02/06Lower Yen Raises Tokyo Stock Market
MT
02/06Jefferies Adjusts Eisai's Price Target to 8,000 Yen From 10,000 Yen, Keeps at Hold
MT
02/06Transcript : Eisai Co., Ltd., Q3 2023 Earnings Call, Feb 06, 2023
CI
02/04Why a new Alzheimer's drug is having a slow US debut
AQ
02/03Interim Report for the period October - December 2022
AQ
01/31Eisai-Biogen Gets Priority Review for Alzheimer's Drug in Japan
MT
01/30Global markets live: Toyota, Unilever, Bayer, Goldman Sachs, Biogen...
MS
01/30It's all about central banks this week
MS
01/30Eisai-Biogen Partnership Pursues Marketing Authorization of Alzheimer's Drug in Europe
MT
More news
Analyst Recommendations on EISAI CO., LTD.
More recommendations
Financials
Sales 2023 746 B 5 623 M 5 623 M
Net income 2023 55 780 M 420 M 420 M
Net cash 2023 175 B 1 319 M 1 319 M
P/E ratio 2023 41,0x
Yield 2023 2,11%
Capitalization 2 189 B 16 498 M 16 498 M
EV / Sales 2023 2,70x
EV / Sales 2024 2,51x
Nbr of Employees 11 322
Free-Float 93,3%
Chart EISAI CO., LTD.
Duration : Period :
Eisai Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EISAI CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 7 631,00 JPY
Average target price 8 950,00 JPY
Spread / Average Target 17,3%
EPS Revisions
Managers and Directors
Haruo Naito Manager-Research & Development Promotions
Tatsuyuki Yasuno Manager-Corporate Planning
Yasuhiko Katoh Chairman
Keisuke Naito Executive Officer & Head-Global IT Headquarters
Yasushi Okada Manager-Business Planning
Sector and Competitors
1st jan.Capi. (M$)
EISAI CO., LTD.-12.33%16 498
JOHNSON & JOHNSON-6.82%427 102
ELI LILLY AND COMPANY-7.31%320 837
NOVO NORDISK A/S2.13%311 923
ROCHE HOLDING AG-2.27%269 272
MERCK & CO., INC.-6.24%263 757